On October 1, 2021 Apexigen, Inc., a clinical-stage biopharmaceutical company focused on discovering and developing a new generation of antibody therapeutics for oncology, reported three upcoming poster presentations at the 36th Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper)’s (SITC) (Free SITC Whitepaper) Annual Meeting, to be held in Washington, D.C., as well as virtually November 10-14, 2021 (Press release, Apexigen, OCT 1, 2021, View Source [SID1234590984]). Sotigalimab, Apexigen’s lead immuno-oncology therapeutic, is a potentially first-in-class and best-in-class CD40 agonist, with unique epitope specificity and Fc receptor engagement for optimal therapeutic effect and tolerability.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Details are as follows:
Title of the Presentation: Phase II of CD40 Agonistic Antibody Sotigalimab (APX005M) in Combination with Nivolumab in Subjects with Metastatic Melanoma with Confirmed Disease Progression on Anti-PD-1 Therapy
Abstract ID: 389
Presenter: Harriet Kluger, M.D., Professor of Medical Oncology at Yale School of Medicine
Title of the Presentation: Multiomic biomarker signatures identify subsets of patients who may benefit from either nivolumab or sotigalimab in combination with chemotherapy in metastatic pancreatic cancer
Abstract ID: 343
Presenter: Deena Maurer, Ph.D., Translational and Regulatory Affairs Scientist Fellow at the Parker Institute for Cancer Immunotherapy
Title of the Presentation: INNATE: Immunotherapy during neoadjuvant therapy for rectal cancer to elucidate local and systemic therapeutic responses
Abstract ID: 411
Presenter: Todd Aguilera, M.D., Ph.D., Assistant Professor of Radiation Oncology at UT Southwestern Medical Center
The posters will be available on-demand through the SITC (Free SITC Whitepaper) conference portal starting Friday, November 12, 2021, at 7:00 a.m. ET.